Skip to main content
Annovis Bio, Inc. logo

Annovis Bio, Inc. — Investor Relations & Filings

Ticker · ANVS ISIN · US03615A1088 LEI · 549300IFBVI51FN3NJ32 US Professional, scientific and technical activities
Open in API
Filings indexed 290 across all filing types
Latest filing 2021-11-17 Regulatory Filings
Country US United States of America
Listing US ANVS

About Annovis Bio, Inc.

https://www.annovisbio.com/

Annovis Bio, Inc. is a clinical-stage drug platform company that develops therapies for neurodegenerative diseases. The company's primary focus is on conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead product candidate, buntanetap, is a translational inhibitor designed to halt the death of nerve cells by targeting the synthesis of multiple neurotoxic proteins. The company's therapeutic approach aims to restore nerve cell function, with the goal of improving cognitive and motor abilities in patients suffering from neurodegeneration.

Recent filings

Filing Released Lang Actions
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. The text indicates that the company is registering its common stock on the New York Stock Exchange, transferring listing from NYSE American LLC. The document includes no financial statements or detailed financial data, but is a regulatory filing for securities registration. It is not an annual report, earnings release, or any other financial report. It is a regulatory announcement related to securities registration, fitting the category of Regulatory Filings (RNS). The document length is 4238 characters, which is relatively short and consistent with a regulatory filing rather than a full report.
2021-11-17 English
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 15, 2021, reporting the transfer of the company's stock listing from the NYSE American to the NYSE. The key content is the announcement of the delisting from one exchange and listing on another. The document includes a press release about this transfer and does not contain financial statements or detailed financial data. The primary subject is the delisting and transfer of listing, which fits the definition of a Delisting Announcement. The document length is 4568 characters, which is sufficient to contain the announcement itself rather than just a brief notice. Therefore, the appropriate classification is DLST (Delisting Announcement).
2021-11-15 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports a press release about new data from a Phase 2a study of a drug, attached as Exhibit 99.1. The document does not contain detailed financial statements or comprehensive financial analysis but rather announces a specific event or update. The length is about 5930 characters, which is relatively short and consistent with a current report rather than a full annual or quarterly report. The content is primarily an event disclosure and press release attachment, typical of a Regulatory Filing (RNS) rather than a full financial report or earnings release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-11-12 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-03 English
Director's Dealing 2021
Director's Dealing
2021-10-13 English
Director's Dealing 2021
Director's Dealing
2021-10-13 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.